Search Results
Your search for it matches 15526 pages
Showing 15401 - 15450ASCO 2013: Adapting to Ongoing Shortages of Common Cancer Drugs
A survey of 214 U.S. oncologists and hematologists found that more than 80% encountered cancer drug shortages between March and September of 2012, and many reported that shortages affected the quality of patient care they were able to provide. As physicians were forced to substitute more expensive...
ASCO 2013: Cervical Cancer Screening Using Visual Inspection with Vinegar Reduces Mortality by 31% in Large Study in India
Cervical cancer mortality was reduced by 31% over a period of 15 years among women screened with biennial visual inspection with acetic acid (VIA), or vinegar, delivered by primary health workers in a large randomized study conducted among 150,000 women in India. The researchers estimate this...
ASCO 2013: 10 Years of Tamoxifen Better Than 5 in Reducing Breast Cancer Recurrence and Death
Ten years of adjuvant treatment with tamoxifen reduces breast cancer recurrence and mortality among women treated for early-stage estrogen receptor (ER)–positive breast cancer, according to results of the British phase III aTTom study. These findings, presented at the 2013 ASCO Annual Meeting ...
ASCO 2013: Sorafenib Stalls Growth of Treatment-resistant Differentiated Thyroid Cancer
A randomized phase III study found that the targeted drug sorafenib (Nexavar) stalls disease progression by 5 months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine therapy. If approved in this setting by the U.S. Food and Drug...
ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival
A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...
ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer
Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...
ASCO President Clifford Hudis, MD, on the 2013 ASCO Annual Meeting
This year’s ASCO Annual Meeting was really exciting in two specific ways. First, we saw the development of high-tech novel therapies and combinations that effectively manipulate the immune system and extend survival in historically difficult-to-treat diseases, like metastatic melanoma (eg,...
ASCO 2013: Cetuximab Offers Survival Advantage over Bevacizumab When Combined with FOLFIRI for First-line Treatment of Advanced Colorectal Cancer
First-line cetuximab (Erbitux) plus FOLFIRI chemotherapy (leucovorin, fluorouracil [5-FU], irinotecan) offered a roughly 4-month survival advantage over bevacizumab (Avastin) plus FOLFIRI for patients with KRAS wild-type metastatic colorectal cancer in the German phase III clinical trial FIRE-3. A ...
In the Clinic: Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was...
ASCO 2013: Selumetinib Significantly Improves Progression-free Survival for Patients with Advanced Melanoma of the Eye
Progression-free survival was significantly improved for patients with metastatic melanoma of the eye (uveal melanoma) treated with selumetinib, according to the final analysis of data from a phase II crossover study presented at the 2013 ASCO Annual Meeting (Abstract CRA9003). Progression-free...
ASCO 2013: Nivolumab Produces Durable Responses in Patients with Stage IV Melanoma
Long-term follow-up results from an expanded phase I study indicate that nivolumab produced long-lasting responses in patients with stage IV melanoma. Overall, 33 out of 107 patients (31%) treated with five different doses of nivolumab experienced tumor shrinkage of at least 30% and responses were...
ASCO 2013: Adding GM-CSF to Ipilimumab Significantly Improves Survival for Patients with Metastatic Melanoma
Adding granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine) to ipilimumab (Yervoy) at a 10 mg/kg dose significantly improved survival compared to the same dose of ipilimumab alone, according to results of a proof-of-principle phase II trial. One year after the start of therapy,...
ASCO 2013: Most U.S. Oncologists Report High Career Satisfaction, but Many Suffer Symptoms of Burnout
Although a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, according to a Mayo Clinic–led study released during the ASCO 2013 Annual Meeting (Abstract 6533). “Oncology can be a tremendously rewarding...
New Method to Test Breast Lesions Could Better Detect Cancer and Reduce Repeat Biopsies
A newly developed, single-step Raman spectroscopy algorithm has the potential to simultaneously detect microcalcifications and enable diagnosis of the associated breast lesions with high precision, according to data published in Cancer Research, a journal of the American Association for Cancer...
New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants
Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology. The study authors attribute the increase to several factors, including advances in HLA...
EGFR Prevents Maturation of Cancer-fighting microRNAs under Hypoxia
Under conditions of oxygen starvation often encountered by tumors, the epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood, the...
Phase II Trial Targeting Genetic Anomaly in Castration-resistant Metastatic Prostate Cancer Underway
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for castration-resistant metastatic prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Physicians have more information to share with their patients about the benefits and risks of low-dose computed tomography (CT) lung cancer screening following the publication in the New England Journal of Medicine of the results of the first (of three planned) annual screening examinations from...
Study: Gold Nanoparticles Can Help Fight Ovarian Cancer
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current...
Molecular Marker from Pancreatic 'Juices' Helps Identify Pancreatic Cancer
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis, two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic “juices” can identify almost all cases of pancreatic cancer, their...
ASCO 2013: New Drug Targeting PI3K-delta Shows Strong Activity in Early Trial for High-risk Chronic Lymphocytic Leukemia
Results from a phase I study of a new oral targeted drug, idelalisib (GS-1101), show the agent has potential as a therapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL). The drug produced rapid and long-lasting tumor shrinkage in half of the patients treated with...
ASCO 2013: Standard-dose Radiation Is Superior to High-dose Radiation for Patients with Locally Advanced Stage III NSCLC Undergoing Chemotherapy
A phase III trial in patients with stage III non–small cell lung cancer (NSCLC) concluded that standard-dose radiotherapy (60 Gy) is safer and more effective than high-dose radiotherapy (74 Gy), extending survival by 9 months and causing fewer treatment-related deaths. While 60 Gy is already...
ASCO 2013: Anti–PD-L1 Drug Shows Promising Anticancer Effects in a Variety of Advanced Cancers
A phase I expansion study of the investigational drug MPDL3280A— an engineered PD-L1 targeted antibody—shows impressive tumor shrinkage rates in patients with several different cancers—including lung, melanoma, kidney, colorectal, and gastric cancers—that had progressed...
ASCO 2013: Men’s Fitness in Middle Age Protects against Developing and Dying from Cancer Later in Life
Findings from a large, prospective 20-year study indicate that a high level of cardiovascular fitness in middle age reduces men’s risk of developing and dying from lung and colorectal cancer, two of the most common cancers affecting men. Better fitness also reduces the risk of dying from,...
ASCO 2013: Phase I Trial Suggests Ipilimumab and PD-1 Drug Nivolumab May Be Better Together than Alone for Advanced Melanoma
Results from a phase I study show that combination therapy with ipilimumab (Yervoy) and the investigational antibody drug nivolumab led to lasting tumor shrinkage in approximately half of patients with aggressive, advanced melanoma. The results will be presented at the 2013 ASCO Annual Meeting in...
Study Identifies Possible New Treatment Target for Acute Leukemia
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with cytogenetically normal acute myeloid leukemia (AML). The study was led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital...
Dual Targeting of Metastatic Breast Cancer Improves Survival Rates
A new study from the USC Norris Comprehensive Cancer Center showed that targeting both hormone receptors and human epidermal growth factor receptor 2 (HER2) in first-line treatment of patients with metastatic breast cancer significantly increased overall survival times. A team of researchers led...
Blocking a Single Gene Renders Tumors Less Aggressive, Johns Hopkins Researchers Find
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called “master regulator” gene may be the key to...
Bladder Cancer Could Recur despite Bladder Removal
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests. The 5-year international study led by researchers at UT Southwestern validates the use of a marker...
FDA Warns about Potential Medication Errors Resulting from Confusion Regarding Nonproprietary Name for Kadcyla (ado-trastuzumab emtansine)
The U.S. Food and Drug Administration (FDA) is alerting health-care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla (ado-trastuzumab emtansine, also known as T-DM1 during preapproval clinical trials) in some medication-related electronic systems...
Emil ‘Tom’ Frei III, MD, Trailblazer in the Development of Combination Chemotherapy, Dies at 89
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
Experimental Drug Beneficial in NIH Trial to Treat a Rare Sarcoma
Patients with advanced alveolar soft part sarcoma achieved some control of their disease using the experimental anticancer drug cediranib. The results from this largest clinical trial on alveolar soft part sarcoma to date were published online ahead of print on April 29, 2013, in the Journal of...
Daratumumab Receives Breakthrough Therapy Designation in Multiple Myeloma
FDA has granted daratumumab breakthrough therapy designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and...
Women Smokers May Have Greater Risk for Colon Cancer Than Men
Smoking increased the risk for developing colon cancer, and female smokers may have a greater risk than male smokers, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “Globally, during the last 50...
Congress Must Reverse Devastating Budget Cuts to Cancer Care
“Today, out of concern for public safety, Congress provided the Federal Aviation Administration enhanced flexibility in application of sequestration related cuts, including reversal of furlough requirements imposed on air traffic controllers. Individuals with cancer deserve no less....
Researchers Identify New Pathway, Enhancing Tamoxifen to Tame Aggressive Breast Cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center (URMC) team has shown how to exploit tamoxifen’s secondary activities so that it might work on more aggressive breast...
Obese Men with Benign Biopsy at High Risk for Prostate Cancer
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the...
Delays in Diagnosis Worsen Outlook for Minority, Uninsured Pediatric Retinoblastoma Patients, Study Finds
When retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive, potentially life-threatening course than in other children, probably because of delays in diagnosis, researchers at Dana-Farber/Children's...
Chernobyl Follow-up Study Finds High Survival Rate among Young Thyroid Cancer Patients
More than a quarter of a century after the Chernobyl nuclear disaster, many children and teenagers who developed thyroid cancer due to radiation are in complete or near remission, according to a recent study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology ...
Bipartisan Group of 124 Lawmakers Express Concern That Medicare Cuts to Life-sustaining Cancer Drugs Threaten Patient Care
The American Society of Clinical Oncology, Community Oncology Alliance, ION Solutions, and The US Oncology Network today commended a bipartisan group of 124 lawmakers in the U.S. House of Representatives who sent a letter to the Centers for Medicare and Medicaid Services (CMS) expressing concern...
New Agent Might Control Breast Cancer Growth and Spread
A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) suggests that an unusual experimental drug can reduce breast cancer aggressiveness, reverse resistance to...
Study to Treat Deadly Form of Thyroid Cancer Shows Promise, Mayo Clinic Says
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, said researchers at Mayo Clinic in Florida. Anaplastic thyroid cancer is one of the deadliest of all cancers. Nearly all patients diagnosed...
Few Breast Cancer Survivors Maintain Adequate Physical Activity Despite Benefits
Breast cancer survivors are among the women who could most benefit from regular physical activity, yet few meet national exercise recommendations during the 10 years after being diagnosed, according to a study by researchers at Fred Hutchinson Cancer Research Center. Prior studies and available...
New Labeling for Reformulated OxyContin to Curb Abuse
The U.S. Food and Drug Administration has approved updated labeling for the reformulated painkiller OxyContin (controlled-release oxycodone hydrochloride). The new labeling will indicate that the drug has physical and chemical properties that make injection or snorting challenging. This new measure ...
The U.S. Supreme Court Hears Arguments Challenging Patents on Breast and Ovarian Cancer Genes
The U.S. Supreme Court heard arguments Monday in a case seeking to invalidate patents on two genes associated with hereditary breast and ovarian cancer. The American College of Medical Genetics and Genomics (ACMG) was one of the first plaintiffs to sign onto this historic legal case. ACMG was also ...
Some Minorities Believe They Are Less Likely to Get Cancer Compared to Whites, Moffitt Cancer Center Study Shows
Researchers at Moffitt Cancer Center and colleagues analyzed national data to investigate the differences in cancer prevention beliefs by race and ethnicity. They found that minorities, including blacks, Asians, and Hispanics, have differing beliefs about cancer prevention and feel they are...
Cryoablation Spot Treats Cancer in the Lung, Extends Survival
Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results were presented on April 14, 2013, at the Society of Interventional Radiology’s 38th Annual Scientific Meeting in New Orleans....
Mammogram Tool Improves Some Breast Cancer Detection but Also Increases False Alarms
A costly and widely used mammography add-on increases detection of noninvasive and early-stage invasive breast cancer but also makes more mistakes than mammography alone, researchers from UC Davis and the University of Washington have found. A new study shows that computer-assisted detection (CAD) ...
